RepliCel Life Sciences Inc. is leading a revolution in the development of products for sports medicine and aesthetics. 

We are a regenerative medicine company developing innovative, clinical-stage technologies for unparalleled skin rejuvenation, tendon regeneration, and hair regrowth.  

RepliCel is currently involved in three clinical development programs:  RCT-01 for treatment of Achilles tendinosis, RCS-01 for skin rejuvenation, and RCH-01 for treatment of Androgenic Alopecia. 

In Asia, RCH-01 is the subject of a co-development partnership with cosmetics and skincare giant Shiseido Company, Limited. Shiseido is currently funding a clinical study for the treatment of male and female pattern baldness (androgenic alopecia) in Japan with data anticipated in late 2018.